Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Kyowa Hakko Sells Amgen Drug Rights For $520 Million

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko Kogyo has agreed to sell the rights to a key cancer and inflammation drug it is developing to Amgen for $520 million. The U.S. biotech is to pay Japan's Kyowa $100 million up-front and the rest during development of humanized monoclonal antibody KW-0761. Under the arrangement, Kyowa subsidiary Kirin Holdings is to retain rights to develop and sell the drug in Japan, South Korea, China and Taiwan, and Amgen elsewhere in the world. The drug is in Phase I trials on lymphoma patients. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068115

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel